Neuraxpharm Pharmaceuticals
As of the edition of 20 October 2026, Neuraxpharm Pharmaceuticals runs 4 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Midazolam | none listed | 1 |
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Methylphenidate | none listed | 11 |
| Ublituximab | Ends 2034 (computed from the first US licence) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Neuraxpharm Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.